← All stories
Tech

GSK (LSE:GSK) approval news tests how blue-chip healthcare absorbs innovation

1 source ·1 article ·4h ago

Highlights A Japanese regulatory decision made Hibsago GSKs first approved chronic hepatitis treatment in any market. The shares softened early, showing that positive regulation and immediate market performance can diverge. Blue-chip resear…

Covered by 1 outlet

All coverage · 1 article